485 related articles for article (PubMed ID: 17339481)
21. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
22. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice.
Kyttaris VC; Kampagianni O; Tsokos GC
Biomed Res Int; 2013; 2013():861028. PubMed ID: 23841097
[TBL] [Abstract][Full Text] [Related]
23. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
24. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.
Liang B; Kashgarian MJ; Sharpe AH; Mamula MJ
J Immunol; 2000 Sep; 165(6):3436-43. PubMed ID: 10975864
[TBL] [Abstract][Full Text] [Related]
25. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
[TBL] [Abstract][Full Text] [Related]
26. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI.
Liu W; Szalai A; Zhao L; Liu D; Martin F; Kimberly RP; Zhou T; Carter RH
Arthritis Rheum; 2004 Jun; 50(6):1884-96. PubMed ID: 15188365
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
28. The central and multiple roles of B cells in lupus pathogenesis.
Chan OT; Madaio MP; Shlomchik MJ
Immunol Rev; 1999 Jun; 169():107-21. PubMed ID: 10450512
[TBL] [Abstract][Full Text] [Related]
29. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
30. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
31. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus.
Bubier JA; Bennett SM; Sproule TJ; Lyons BL; Olland S; Young DA; Roopenian DC
Ann N Y Acad Sci; 2007 Sep; 1110():590-601. PubMed ID: 17911475
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
33. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
34. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
35. IgG1 and IgG2a production by autoimmune B cells treated in vitro with IL-4 and IFN-gamma.
Klinman DM
J Immunol; 1990 Apr; 144(7):2529-34. PubMed ID: 2108205
[TBL] [Abstract][Full Text] [Related]
36. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells.
Mandik-Nayak L; Seo SJ; Sokol C; Potts KM; Bui A; Erikson J
J Exp Med; 1999 Jun; 189(11):1799-814. PubMed ID: 10359584
[TBL] [Abstract][Full Text] [Related]
37. Effect of combining ACE inhibitor and statin in lupus-prone mice.
Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M
Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
[TBL] [Abstract][Full Text] [Related]
38. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F
J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.
Shimp SK; Chafin CB; Regna NL; Hammond SE; Read MA; Caudell DL; Rylander M; Reilly CM
Cell Mol Immunol; 2012 May; 9(3):255-66. PubMed ID: 22543833
[TBL] [Abstract][Full Text] [Related]
40. CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production.
Shi L; Bian Z; Chen CX; Guo YN; Lv Z; Zeng C; Liu Z; Zen K; Liu Y
J Pathol; 2015 Nov; 237(3):285-95. PubMed ID: 26095930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
